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The basis of chronic infection following exposure to hepatitis C virus (HCV) infection is unexplained. One
factor may be the low frequency and immature phenotype of virus-specific CD8 T cells. The role of
CD4CD25 T regulatory (Treg) cells in priming and expanding virus-specific CD8
 T cells was investigated.
Twenty HLA-A2-positive patients with persistent HCV infection and 46 healthy controls were studied. Virus-
specific CD8 T-cell proliferation and gamma interferon (IFN-) frequency were analyzed with/without
depletion of Treg cells, using peptides derived from HCV, Epstein-Barr virus (EBV), and cytomegalovirus
(CMV). CD4CD25 Treg cells inhibited anti-CD3/CD28 CD8
 T-cell proliferation and perforin expression.
Depletion of CD4CD25 Treg cells from chronic HCV patients in vitro increased HCV and EBV peptide-
driven expansion (P  0.0005 and P  0.002, respectively) and also the number of HCV- and EBV-specific
IFN--expressing CD8 T cells. Although stimulated CD8 T cells expressed receptors for transforming
growth factor beta and interleukin-10, the presence of antibody to transforming growth factor beta and
interleukin-10 had no effect on the suppressive effect of CD4CD25 regulatory T cells on CD8 T-cell
proliferation. In conclusion, marked CD4CD25 regulatory T-cell activity is present in patients with chronic
HCV infection, which may contribute to weak HCV-specific CD8 T-cell responses and viral persistence.
There are 170 million patients worldwide with persistent
hepatitis C virus (HCV) infection who are at significant risk of
progressive liver injury leading to cirrhosis, death from liver
failure, and liver cancer (2, 11, 22). There is a crucial need to
delineate the underlying pathogenesis. One important aspect
of persistent HCV infection may be the low frequency of cir-
culating HCV-specific CD8 T cells (13, 23), despite high-level
viral replication and viral protein production. This is in marked
contrast to acute infection, where the CD8 T-cell response
may comprise 8% of total CD8 T cells and include responses
to at least eight separate epitopes (24). If viremia persists after
acute infection, CD8 T-cell responses wane rapidly (23).
It has been argued that T-cell exhaustion (20) or viral mu-
tation (12, 20) may cause the low number of circulating anti-
gen-specific CD8 T cells during HCV infection. The failure of
HCV-specific CD8 T cells to expand may be important in
viral persistence, as it has been recently shown that a strong
CD8 T-cell response in the chimpanzee model correlates with
protection against reinfection and is associated with viral clear-
ance during primary infection (37). Furthermore, in nonvire-
mic HCV antibody-positive patients, HCV-specific CD8 T
cells expand more readily compared to viremic patients (39).
Few studies have addressed the reasons for either the low
frequency of HCV-specific CD8 T cells or the immature
phenotype associated with persistent HCV viremia (27). One
possible mechanism may be regulation by CD4CD25 regu-
latory T cells (Treg) (38). A recent study has shown an increase
in CD4CD25 Treg cells during chronic HCV infection and
that these cells may secrete interleukin (IL)-10 and transform-
ing growth factor beta (TGF-) (7). In addition, HCV-specific
gamma interferon (IFN-) secretion by peripheral blood
mononuclear cells (PBMC) could be recovered or increased by
the addition of anti-TGF-.
Secondary memory CD8 T-cell responses in a murine model
are controlled by CD4CD25 Treg cells (30). This is in contrast
to primary immune responses, which are dependent on CD4
T-cell help (19). In murine and human studies, CD4CD25 Treg
cells have been characterized by intracellular expression of cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) and have im-
portant roles in the prevention of autoimmune disease (29, 35, 36)
and transplantation tolerance (9, 17, 33, 41). Secreted IL-10 and
membrane-bound TGF- may both be critical to CD4CD25
Treg cell function (14, 15), although in vitro data are inconclusive
(8). We addressed the hypothesis that HCV-specific CD8 T-cell
expansion in chronic HCV infection may be controlled by
CD4CD25 Treg cells.
MATERIALS AND METHODS
Study subjects and samples. Twenty HCV antibody-positive, HCV RNA-
positive, HLA-A2-positive patients were selected from a cohort of outpatients in
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Cambridge, United Kingdom. Peripheral blood mononuclear cells (PBMC) were
obtained from patients by centrifugation of heparinized blood over Lymphoprep
(Nycomed, Roskilde, Denmark). PBMC were also isolated from six HLA-A2-
positive healthy individuals with serological evidence of past cytomegalovirus
(CMV) and/or Epstein-Barr virus (EBV) infection. All samples were obtained
with approval of the Local Ethics Research Committee. Patient details are shown
in Table 1.
Cell isolation. In the initial regulatory T-cell characterization experiments in
Fig. 1 and 2, CD4CD25 cells were first isolated by negative depletion of CD4
T cells from PBMC and the CD25 T cells were purified from this CD4 fraction
by magnetic depletion using mouse anti-human CD25 beads as per the manu-
facturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany) and sep-
arated into CD25 (referred to as CD4CD25) or CD25 cells (referred to as
CD4CD25). All further experiments were performed using CD25 T cells
isolated from PBMC (also referred to as CD4CD25) by magnetic depletion
using mouse anti-human CD25 beads. Fluorescence-activated cell sorting anal-
ysis after depletion showed that over 85% of the isolated CD25 cells were
CD4. In the CD25-depleted PBMC fraction, 5% of the original CD25
population was detectable. In addition, CD8 T cells were isolated using mouse
anti-human CD8 beads (Miltenyi Biotec).
Flow cytometric analysis. The following conjugated antibodies and additional
fluorometric reagents were used: CD4-fluorescein isothiocyanate (FITC)/Cy-
Chrome, CD8-CyChrome, CD25-phycoerythrin (PE), CTLA-4-CyChrome, Ki-
67-FITC, IL-10 receptor-PE (all from BD Pharmingen, Oxford, United King-
dom), TGF- receptor type II-FITC, active TGF--biotinylated (R&D Systems,
Minneapolis, MN), and streptavidin-PE (BD Pharmingen). HLA class I peptide
tetramers were prepared as previously described (3) and included tetramers
specific for five epitopes restricted by HLA-A2: HCV-NS3 peptides 1073 to 1081,
CINGVCWTV; HCV-NS4 peptides 1406 to 1415, KLVALGINAV; HCV-NS5b
peptides 2594 to 2603, ALYDVVTKL; CMV-pp65 peptides 495 to 503 NLVP-
MVATV; and EBV-BMLF1 peptides 280 to 288, GLCTLVAML. All peptides
were synthesized by Research Genetics (Invitrogen, Paisley, United Kingdom).
Tetramer staining was performed as previously described (26). Cells were ac-
quired on a FACSCalibur and analyzed using Cellquest software (BD Pharmin-
gen). Intracellular staining was performed according to the manufacturers’ in-
structions (Cytofix/Cytoperm; BD Pharmingen).
Proliferation assays. We plated 105 cells per well of CD4CD25 Treg,
CD4CD25 and CD8 T cells separately or in specific combinations in a
96-well round-bottom plate. Samples were prepared in triplicate, and anti-CD3
(1 g/ml) and anti-CD28 (1 g/ml) (BD Pharmingen) were added to each well
to a total volume of 200 l. Proliferation was then determined on day 5 either by
thymidine incorporation or by flow cytometric analysis using Ki-67 as a nuclear
marker of cell proliferation. Proliferation was assessed by incorporation of 0.5
Ci/well [3H]thymidine (Amersham Pharmacia, Little Chalfont, United King-
dom) after culture and 6 h prior to harvesting. PBMC were collected onto filters
using an automatic cell harvester (Wallac, Turku, Finland) and incorporated
[3H]thymidine was measured using a -counter (Wallac). The results were ex-
pressed as counts per minute (cpm) minus the mean cpm for the control wells.
Cell counts did not differ by more than 10% (n  6) for the CD4CD25 cells
when performed on days 0 and 5 after anti-CD3/CD28 treatment.
Peptide restimulation. PBMC, depleted or not depleted of CD25 cells using
CD25 beads (Miltenyi Biotec), were restimulated in 48-well plates (5  105
cells per well) with 10 g/ml peptide in 1 ml of RPMI 1640, 10% human AB
serum (First Link, United Kingdom), 100 g/ml streptomycin, 100 U/ml peni-
cillin, and 2 mM glutamine (RPMI-10) and incubated at 37°C in a humidified
CO2 (5%) incubator. On days 3 to 4, 500 l of RPMI-10 containing 200 U/ml of
recombinant interleukin-2 (Chiron, Emeryville, CA) was added, and further
medium changes with 100 U/ml of recombinant interleukin-2 were performed
every 3 to 4 days until they were analyzed on day 14. In parallel, CD4CD25
Treg cell-depleted PBMC were incubated with the CD4CD25 Treg cells
(termed repletion) at ratios of 1:2 and 1:10 (CD4CD25 Treg cells:depleted
PBMC). CD4CD25 Treg cell repletion was also performed in the presence of
200 U/ml and 400 U/ml of IL-2 on day 0. After 14 days, the percentage of
tetramer-specific CD8 T cells was determined. Cytokine blocking experiments
were also performed using antibodies to TGF- or IL-10 (10 g/ml) (R&D
Systems).
Enzyme-linked immunospot assays. CD4 T-cell IFN- ELISpot assays were
performed on 2  105 PBMC with or without CD25 cells (n  6). Cells were
preincubated for 24 h in the presence of a pool of three HCV peptides, an EBV
peptide (10 g/ml), or phytohemagglutinin (at 1 g/ml; Sigma, Dorset, United
Kingdom). In parallel, 96-well Immobilon-P membrane microtiter plates (Milli-
pore, Bedford, MA) were coated with 100 l of 5 g/ml anti-IFN- monoclonal
antibody in a human IFN- enzyme-linked immunospot (ELISpot kit; BD Bio-
sciences). These plates were incubated for 16 h at 4°C, after which they were
washed and then blocked with RPMI-10 for 2 h. The medium was removed and
the preincubated cell cultures were transferred to the Immobilon-P plates and
incubated for a further 24 h. Following this, plates were washed with water and
then with phosphate-buffered saline (PBS)/0.5% Tween-20; 100 l of 2 g/ml
detection biotinylated anti-IFN- was added to each well and incubated for 2 h
at room temperature. The plates were washed again, and 100 l of avidin-
horseradish peroxidase conjugate was added to each well and incubated for 1 h
at room temperature. Unbound conjugate was removed by thorough washing,
and finally 100 l of AEC (3-amino-9-ethylcarbazole) substrate was added to
each well for exactly 15 min. The reaction was stopped with extensive washing
with water. The plates were dried overnight at room temperature and the spots
were counted by the AID ELISpot reader system (AID Diagnostika GmbH,
Strassberg, Germany). The number of specific spot-forming cells was determined
as the mean number of spots in the presence of an antigen minus the mean
number of spots in the wells with medium only and expressed per 106 PBMC.
Isolation of intrahepatic lymphocytes. Fresh liver tissue was obtained from six
viremic patients at diagnostic biopsy. Samples were placed in RPMI supple-
mented with 10% fetal bovine serum and 0.02% EDTA, disaggregated using
21-gauge needles, and the cell suspension was filtered through nylon mesh.
Hepatocytes were removed by centrifugation at 50  g. The supernatant was
centrifuged at 2,000  g and the pellet was washed twice in PBS and suspended
in RPMI. The yield of mononuclear cells was 1.5 to 5  105.
Immunohistochemistry of intrahepatic lymphocytes. Formalin-fixed, paraffin-
embedded sections (5 m) on 3-aminopropyltriethoxysilane (APES)–coated
slides were dewaxed in xylene and taken through a series of ethanol washes. The
tissues were pressure-cooked in 0.08 M citrate buffer (pH 6.0) for 3 min to
facilitate antigen retrieval. Following washes in Tris-buffered saline (TBS), en-
dogenous peroxidase activity was quenched by incubation in 0.6% hydrogen
peroxide in TBS and blocked with appropriate serum (10% rabbit) in TBS for 2 h
(DAKO, United Kingdom). A goat polyclonal Foxp3 (ABCAM, United King-
dom) was applied (100 l) in a humidified chamber at 4°C overnight with gentle
shaking in 1% bovine serum albumin/TBS with 0.1% Triton X-100. The slides
were washed in TBS containing 0.025% Triton X-100 and incubated for 1 h with
rabbit anti-goat Foxp3. A streptavidin-horseradish peroxidase system (DAKO,
United Kingdom) with the substrate diaminobenzidine was used for develop-
ment. Slides were counterstained with Harris hematoxylin, dehydrated in etha-
nol, and cleared in xylene. Coverslips were applied with DPX mounting medium
(Gurr, United Kingdom). Omission of the primary antibody served as a negative
control.
Statistical analysis. In paired experiments, the distribution of the data was
assumed to be nonparametric. The medians of the data sets were then compared
using a Wilcoxon signed rank test. Statistical analysis was performed on SPSF
version 11.5. Significant values (P  0.05) are indicated.
TABLE 1. Chronically HCV-infected patient data
Case
no. Sex Genotype Ethinicity
ALTa
(IU/ml)
Fibrosis
Score (0–6)
1 M 1 Caucasian 78 4
2 M 1 Caucasian 102 2
3 M 1 Caucasian 98 3
4 F 1 Caucasian 106 0
5 M 1 Caucasian 56 2
6 F 1 Caucasian 63 2
7 M 2 Caucasian 53 3
8 M 1 Asian 111 1
9 M 1 Caucasian 107 1
10 M 3 Caucasian 42 2
11 F 1 Asian 124 2
12 F 2 Caucasian 143 3
13 M 1 Caucasian 88 2
14 M 1 Caucasian 92 2
15 F 2 Caucasian 87 2
16 M 2 Caucasian 131 3
17 M 1 Caucasian 152 5
18 M 1 Caucasian 56 6
19 M 1 Caucasian 51 4
20 M 3 Caucasian 69 3
a ALT, alanine aminotransferase.
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RESULTS
CD4CD25 Treg cells from patients with HCV do not pro-
liferate and regulate both CD4CD25 and CD8 T-cell pro-
liferation. To determine whether the CD4CD25 T-cell pop-
ulation had suppressor function in persistent HCV infection
and whether the cells isolated in these experiments were com-
parable with those in other studies, classical T-cell suppression
assays were performed in six patients. Isolated CD4CD25
Treg cells did not proliferate after nonspecific soluble anti-CD3
stimulation. In contrast, CD4CD25 T cells proliferated, and
this was abrogated in coculture with CD4CD25 Treg cells at
a 1:1 ratio. (Fig. 1A). In addition, increased expression of
intracellular CTLA-4 was present in CD4CD25 Treg cells
(Fig. 1B) compared to CD4CD25 T cells (Fig. 1C).
To examine the frequencies of CD25 T cells in liver (a
likely site of activity), the percentage of CD4CD25 Treg cells
(median 8.95%) and CD8 T cells (median 17.9%) was deter-
mined from liver biopsies of 6 chronic HCV patients (Fig. 1D).
Therefore an approximate ratio within the liver of
CD4CD25 Treg cell: CD8
 T cells is 1:2. Foxp3 stained liver
histology samples were also analyzed (Fig. 1E), which indi-
cated that CD4CD25 Treg cells appear to predominate
around the portal tract. Therefore, the CD4CD25 Treg cell:
CD8 T-cell ratio may vary significantly within various com-
partments of the liver.
To determine whether the CD4CD25 Treg cells could also
suppress the proliferation of CD8 T cells during persistent
HCV infection, the latter were stimulated with anti-CD3/anti-
CD28. Proliferation of CD8 T cells, measured by nuclear
Ki-67 expression, was inhibited by coculture with CD4CD25
Treg cells in a 1:1 ratio (P  0.05, n  6; Fig. 2A-B).
CD4CD25 Treg cells also suppressed the expression of in-
tracellular perforin in activated CD8 T cells (P  0.05; n 
6; Fig. 2D). Group data of Ki-67 and perforin expression are
FIG. 1. Function and phenotype of CD4CD25 cells from patients with persistent HCV infection. (A) CD4CD25 Treg cells, CD4
CD25
T cells, or a combination of these at a ratio of 1:1 were stimulated with anti-CD3 and cell proliferation was measured using [3H]thymidine
incorporation. (B and C) Intracellular CTLA-4 expression of (B) CD4CD25 cells and (C) CD4CD25 cells. (D) Percentage of CD8 and
CD4CD25 cells within the intrahepatic lymphocyte population. (E) Histological staining for Foxp3 within the liver of an HCV-infected
individual.
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shown in Fig. 2C and E, respectively. The inhibitory effect of
CD4CD25 Treg cells on CD8
 T-cell expansion could not be
reversed by culture with antibody to either TGF- or anti-
IL-10 (Fig. 2C).
CD4CD25 Treg cells regulate proliferation of HCV-spe-
cific CD8 T cells. The frequency of HCV-specific CD8 T
cells after in vitro expansion with peptide increased with de-
pletion of CD4CD25 Treg cells (P  0.0005, Fig. 3A, top
panel; Fig. 3B, top panel summarizes the 12 individual re-
sponses). In 12/20 patients studied, there was a significant
increase (as determined by the size of the tetramer response)
in antigen-specific CD8 T-cell expansion to at least one of the
three HCV peptides studied following depletion of
CD4CD25 Treg cells. In 5 of those 12 patients, the HCV-
specific CD8 T-cell response was undetectable after restimu-
lation of PBMC until depletion of CD4CD25 Treg cells. For
the 12 individual peptide responses there was a median 43-fold
increase in the size of the tetramer response following deple-
tion of CD4CD25 Treg cells (P  0.0005).
To determine if this effect was HCV specific or extended to
other virus-specific CD8 T- cell responses, the effect of
CD4CD25 Treg cell depletion on CMV- and EBV-specific
CD8 T-cell responses was studied. Five of the patients had
serological evidence of previous CMV infection and 15 had
serological evidence of previous EBV infection.
The tetramer frequency of CMV-specific CD8 T cells also
increased (median, sixfold) in all five CMV-positive individuals
following depletion of CD4CD25 Treg cells (Fig. 3A, middle
panel; Fig. 3B, middle panel summarizes group data) (P 
0.043). The frequency of EBV-specific CD8 T cells also in-
creased (median 3 fold) in 14/15 patients following depletion
of CD4CD25 Treg cells (Fig. 3A, bottom panel; Fig. 3B,
bottom panel summarizes group data) (P  0.002).
Addition of CD4CD25 Treg cells suppresses antigen-spe-
cific CD8 T-cell proliferation. Isolated CD4CD25 Treg
FIG. 2. Inhibition of CD8 T-cell proliferation and perforin ex-
pression by CD4CD25 Treg cells. (A) CD8
 T cells or (B) CD8 T
cells in the presence of CD4CD25 Treg cells were stimulated with
anti-CD3/CD28 and stained with anti-Ki-67, a nuclear marker of pro-
liferation. Histograms are gated on CD8 T cells. (C) The proportion
of Ki-67-positive CD8 T-cell was reduced in the presence of
CD4CD25 Treg cells (coculture; n  6) and was not restored upon
addition of anti-IL-10 or anti-TGF- antibodies. (D) Intracellular per-
forin expression of anti-CD3/CD28 activated CD8 T cells with (grey
filled) or without CD4CD25 Treg cells (black line) at a 1:1 ratio.
(E) The proportion of intracellular perforin-positive CD8 T cells was
reduced in the presence of CD4CD25 Treg cells (coculture; n  6).
Horizontal bars represent median values, the box represents the inter-
quartile range, and the error bars represent the range.
FIG. 3. CD4CD25 Treg cells suppress the expansion of virus-
specific CD8 T cells during HCV infection. Proliferation in response
to peptide stimulation was measured by tetramer frequency. Examples
of individual patients are shown: (A) PBMC alone (left-hand panels)
and CD4CD25 Treg-depleted PBMC (right-hand panels) were re-
stimulated with HCV-specific (top panels), CMV-specific (middle pan-
els), or EBV-specific (bottom panels) peptides, and the extent of
proliferation was measured by tetramer frequency. (B) Overall results
are shown for HCV (top panel), CMV (middle panel), and EBV
(bottom panel). The left-hand box represents the responses in unfrac-
tionated PBMC, the right-hand box represents the responses following
depletion of CD4CD25 Treg cells. Horizontal bars represent median
values, the box represents the interquartile range, and the error bars
represent the range.
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cells were added back to the depleted PBMC population prior
to restimulation. Almost total abolition of HCV-specific CD8
T-cell responses was seen in 11/12 patients at ratios of 1:2 and
1:10 (CD4CD25 Treg cells: CD4
CD25 Treg-depleted
PBMC) (Fig. 4A, left-hand side panels; Fig. 4B). All 5 CMV-
specific CD8 T-cell responses were suppressed by repletion of
CD4CD25 Treg cells. (Fig. 4, right-hand side panels). The
effect of adding back CD4CD25 Treg cells (repletion) could
not be overcome by supplementation with IL-2 (Fig. 4B).
Overall, depletion of CD4CD25 Treg cells led to a signif-
icant increase in the expansion of HCV-specific CD8 T cells
in HCV-infected individuals (Fig. 5A). A consistent but less
marked increase in CMV- and EBV-specific responses after
restimulation was also seen in HCV infected patients. No sig-
nificant effect was seen on either EBV- or CMV-specific CD8
T-cell expansion following depletion of CD4CD25 Treg cells
in six healthy individuals (Fig. 5A).
CD4CD25 Treg cells control HCV CD8
 T-cell IFN-
secretion. An ELISpot to quantify the number of IFN--se-
creting HCV-specific CD8 T cells was used to analyze the
effects of CD4CD25 Treg cells in short-term assays. Six
patients from the original cohort of 20 were selected such that
three had increased HCV tetramer frequency following deple-
tion of CD4CD25 Treg cells, while 3 did not (negative con-
trol) and all six had detectable EBV responses. Increased num-
bers of IFN- HCV-specific CD8 T cells were seen with 3
pooled HCV peptides following CD4CD25 Treg cell deple-
tion in all three responders (Fig. 5B). IFN- HCV-specific
CD8 T cells were not detected in nonresponders pre- or
post-CD4CD25 Treg cell depletion. However, increased
numbers of IFN- EBV-specific CD8 T cells were seen
following CD4CD25 Treg cell depletion in all 6 patients
(Fig. 5C).
HCV-specific CD8 T cells ex vivo do not express TGF-
and IL-10 receptors. Activated CD4CD25 Treg cells express
membranous TGF- and secrete IL-10 (6, 14, 25). TGF- and
IL-10 receptor expression on virus-specific CD8 T cells was
therefore determined. HCV-specific CD8 T cells (n  4)
revealed no expression of TGF- and IL-10 receptors (Fig. 6 A
and B). Similarly, CMV-specific CD8 T cells revealed little
expression of either the TGF- receptor (Fig. 6C) or IL-10
receptor ex vivo (Fig. 6D). Expression of both receptors on
tetramer-positive cells was observed, however, after in vitro
peptide stimulation (Fig. 6E and F). CMV- and EBV-specific
CD8 T cells from healthy individuals had similar levels of
IL-10 and TGF- receptor expression ex vivo (i.e., 3%; n 
3) which, also increased after peptide stimulation (data not
shown).
DISCUSSION
Hepatitis C is a major pandemic that affects more than 170
million people worldwide. Persistent infection is associated
with ineffective CD4 and CD8 T-cell responses. The causes
of T-cell failure are unclear but may include viral variation,
T-cell exhaustion, dysfunction of dendritic cells, modulation by
specific viral proteins such as core, and intrahepatic death of T
cells (6, 40). Another hallmark of the poor response is lack of
CD8 T-cell maturation despite initial priming and continued
antigen exposure (4, 16). We proposed that CD4CD25 Treg
cells, which regulate human and mouse CD4 and CD8 T-
cell function, could modulate HCV-specific CD8 T-cell re-
sponses.
CD4CD25 Treg cells isolated from patients with persis-
FIG. 4. Repletion of CD4CD25 Treg cells to CD4
CD25 Treg
cell-depleted PBMC inhibits CD8 T-cell peptide-induced prolifera-
tion. Proliferation in response to peptide stimulation was measured by
tetramer frequency. Examples are shown with HCV peptide-specific
(left-hand panels) or CMV peptide-specific (right-hand panels) expan-
sions. CD4CD25 Treg-depleted PBMC (top panels), repletion of
CD4CD25 Treg-depleted PBMC with CD4
CD25 Treg cells at 1:10
(middle panels), or 1:2 (CD4CD25 Treg cell: PBMC) (bottom pan-
els). (B) Group data (n  12) of HCV-specific tetramer frequency
following peptide restimulation with or without the addition of
CD4CD25 Treg cells. Repletion of CD4
CD25 Treg cells was also
performed with the addition, on day 0, of IL-2 at concentrations of 200
U/ml and 400 U/ml.
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tent HCV infection were hypo-proliferative and expressed in-
tracellular CTLA-4. They inhibited anti-CD3 stimulated
CD4CD25 proliferation, anti-CD3/anti-CD28 CD8 T-cell
proliferation, and HCV peptide-driven T-cell proliferation,
consistent with functional human and murine studies of the
CD4CD25 Treg cell subset. CD4
CD25 Treg cells also
inhibited acquisition of CD8 T-cell perforin and IFN- ex-
pression.
The CD4CD25 Treg:CD8
 T-cell ratio used in these co-
culture experiments was high considering ratios of cells in
peripheral blood. However, the ratio of CD4CD25 Treg cells
to CD8 T cells, as we show, may be relatively high, and
particularly within portal tracts, where their effects may be
relevant. The percentage of CD4CD25 Treg cells within the
liver (	9%) differs significantly from that of another recent
study (7). However, the percentage within this study was de-
termined in livers at the time of transplantation, which indi-
cates that these livers may be cirrhotic and thus differ from
livers studied at earlier stages of disease.
The mechanism of action of CD4CD25 Treg cells was not
addressed directly. It is thought that TGF- and IL-10 play
important roles in CD4CD25 Treg cell control in autoim-
mune disease (5, 28, 32). Circulating HCV-specific CD8 T
cells exhibit no expression of TGF- and IL-10 receptors, and
only weak expression was seen on EBV- or CMV-specific
CD8 T cells. However, both receptors were readily up-regu-
lated upon stimulation, which indicates that TGF- and IL-10
may have an alternate suppressive role on activated CD8 T
cells.
To date, in vitro experiments have failed to conclusively
define a role for TGF- or IL-10 in human CD4CD25 Treg
cell function (8). However, this does not exclude a role in vivo.
A recent study has shown an effect of TGF- but not IL-10 on
HCV-specific CD8 T cells during chronic HCV infection (7).
This study identified TGF--secreting antigen-specific CD4 T
FIG. 5. Virus-specific responses are suppressed by CD4CD25
Treg cells in HCV patients compared to healthy individuals. (A) The
ratio of the specific CD8 T-cell increase following CD4CD25 Treg
cell depletion over PBMC alone of all patients studied. The EBV- and
CMV-specific responses in healthy individuals are in the left column,
the EBV- and CMV-specific responses in HCV-infected patients are in
the middle column, and the HCV-specific responses in HCV-infected
patients are in the right column. The horizontal line in each column
represents the median. (B) Depletion of CD4CD25 Treg cells en-
hances IFN- secretion by virus-specific CD8 T-cell in HCV-infected
patients. PBMC alone (PBMC) and following depletion of
CD4CD25 Treg cells (Depleted) were used in an IFN- ELIspot
assay using a pool of three HCV peptides or (C) the EBV peptide.
FIG. 6. Expression of the TGF- receptor type II and IL-10 recep-
tors on virus-specific CD8 T cells. (A) TGF- receptor type II and
(B) IL-10 receptor expression on HCV-specific CD8 T cells ex vivo.
(C) TGF- receptor type II and (D) IL-10 receptor expression on
CMV-specific CD8 T cells ex vivo. (E) TGF- receptor type II and
(F) IL-10 receptor expression on CMV-specific CD8 T cells after
peptide restimulation.
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cells and analyzed the effect of anti-TGF- antibody on IFN-
expression by PBMC. It also showed that the suppression of
proliferation of CD4CD25 T cells was contact dependent.
Our data, together with those of Boettler et al. (6a), also
suggest that the suppression of proliferation (in the case of
CD8 T cells) is contact dependent. However, in both of these
studies proliferation was not inhibited by anti-TGF- antibody.
These data potentially suggest that assays of different CD8
T-cell functions may identify distinct activities of membrane-
bound and secreted TGF-. Potential differences in activity of
CD4CD25 Treg cells on HCV-specific CD4
 and CD8 T
cells requires further investigation.
The significant increase in proliferation for all virus-specific
CD8 T cells in the absence of CD4CD25 Treg cells in
patients with chronic HCV infection suggests that these cells
are capable of controlling expansion of CD8 T cells during
HCV infection. Furthermore when CD4CD25 Treg cells
were added back to depleted PBMCs, proliferation was re-
duced. These findings are consistent with a murine study in
which depletion of CD4CD25 Treg cells enhanced second-
ary proliferation of CD8 T-cell memory responses (30). In
addition, we have shown that the suppression is not due to
removal of IL-2 by CD4CD25 Treg cells as has previously
been suggested (10). High doses of IL-2 added at the time of
peptide stimulation or thereafter had no effect on the lack of
proliferation seen in the repletion experiments and, together
with the cell-cell contact dependent mechanism of inhibition,
indicate that IL-2 has no role in suppression.
The finding that the depletion of CD4CD25 Treg cells in
patients with chronic HCV also enhanced expansion of EBV-
and CMV-specific CD8 T cells was not mirrored in healthy
controls. This may suggest that CD4CD25 Treg cells are
more active in patients with chronic HCV and have effects on
non-HCV-specific CD8 T cells. These data are also consis-
tent with recent evidence of inhibition of maturation of CMV-
specific CD8 T cells in persistent HCV infection (27). Our
own and previous published data have also indicated that
CD8 T-cell maturation is inhibited in chronic HCV infection,
as measured by reduced perforin expression (27, 31).
Therefore, a proposed mechanism by which suppression of
proliferation and differentiation of CD8 T cells during HCV
infection occurs at the immature central memory T-cell phase
could contribute to the apparent immaturity of CD8 T cells in
addition to the low frequency of HCV-specific CD8 T cells.
The frequency of other virus-specific CD8 T-cell responses
(such as CMV) has not been shown to alter during HCV
infection (18, 34), although these populations are very variable
between individuals and may change with age (21). It is likely
that such T-cell populations are established prior to HCV
infection. Thus, the overall consequences may be an impact of
HCV persistence on the maturation state of CMV and bulk
CD8 T cells rather than a decrease in the precursor pool.
Additionally, the suppressive effect on EBV- and CMV-spe-
cific CD8 T-cell responses was not as high as the effect on the
HCV response (Fig. 5A), which may allow those former pop-
ulations to maintain a relatively higher frequency.
These data confirm and extend recent studies of the role of
CD4CD25 Treg cells in chronic human virus infections. One
study of HCV, based upon depletion of CD4 T cells, revealed
increased numbers of IFN--secreting cells (38). A further
study in human immunodeficiency virus infection also sug-
gested CD4CD25 Treg cell activity in chronic infection (1).
Neither of these studies addressed the influence of such cells
on proliferation and maturation. The inhibitory effect of
CD4CD25 Treg cells on CD8
 T-cell expansion and func-
tion may be one mechanism whereby chronic HCV infection is
associated with limited CD8 T-cell expansion and matura-
tion. It may represent a direct effect of the virus or be part of
the normal response to chronic inflammation, either hepatic or
systemic.
Our results complement and are reinforced by another
group (6a) that used CD4 depleted PBMC to show the same
suppression of virus-specific CD8 T-cell proliferation in both
chronic and resolved HCV patients but not in healthy individ-
uals. Their results also show similar suppression of virus-spe-
cific CD8 T-cell proliferation (HCV- and influenza virus-
specific responses, compared to our HCV-, EBV- and CMV-
specific responses) and were also able to demonstrate that this
effect was cell-contact dependent and showed similar potency
in titration experiments. Similarly, they were also able to show
that this effect was TGF- and IL-10 independent.
These results provide a plausible explanation for the low
frequencies and retarded maturation state (low perforin and
IFN- expression) of HCV-specific CD8 T cells seen in per-
sistently infected patients and indicate that modulation of
CD4CD25 Treg cell function may be one therapeutic strat-
egy for the treatment of chronic HCV.
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